Decoy Therapeutics Announces Reverse Stock Split to Maintain Listing

Decoy Therapeutics ( (DCOY) ) has provided an update.

Decoy Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on AI-enabled peptide conjugate therapeutics for respiratory viruses and gastrointestinal cancers, has built a diversified funding base from institutional investors and non-dilutive sources including the Massachusetts Life Sciences Seed Fund, Google’s AI startup program, NVIDIA Inception and BARDA’s BLUE KNIGHT initiative. This positioning underscores its strategy to marry advanced computation with rapid synthesis to address serious unmet medical needs.

At a special meeting on February 24, 2026, Decoy’s stockholders authorized a reverse stock split, and on February 25, 2026, the board approved a 1-for-12 split that will take effect at 5:00 p.m. Eastern on March 6, 2026, with split-adjusted trading on Nasdaq beginning March 9, 2026 under the existing ticker DCOY and a new CUSIP. The move, which will reduce outstanding common shares from about 6.38 million to roughly 532,000 without changing authorized share counts, is designed to regain compliance with Nasdaq’s minimum bid price rules and preserves proportional ownership for shareholders except for minor cash-in-lieu payments on fractional shares.

All outstanding options, warrants, restricted stock units and equity plan reserves will be proportionally adjusted to reflect the new share count, with Equiniti Trust Company acting as exchange and transfer agent for the process. The reverse split, first announced in a press release dated August 14, 2025 and formalized through a Certificate of Amendment filed in Delaware on March 5, 2026, marks a key step in Decoy’s effort to maintain its Nasdaq Capital Market listing and could stabilize market perception by lifting the per-share price even as the overall market capitalization remains largely unchanged.

The most recent analyst rating on (DCOY) stock is a Sell with a $0.72 price target. To see the full list of analyst forecasts on Decoy Therapeutics stock, see the DCOY Stock Forecast page.

Spark’s Take on DCOY Stock

According to Spark, TipRanks’ AI Analyst, DCOY is a Neutral.

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by a low-debt balance sheet. Technicals are also a headwind with a longer-term downtrend and negative MACD, while valuation is constrained by continued losses and no dividend data.

To see Spark’s full report on DCOY stock, click here.

More about Decoy Therapeutics

Decoy Therapeutics Inc. is a preclinical-stage biotechnology company that uses machine learning, artificial intelligence and high-speed synthesis to design and manufacture next-generation peptide conjugate drug candidates. Its initial pipeline targets serious unmet medical needs in respiratory viruses and gastrointestinal cancers, and it is backed by institutional investors and non-dilutive funding from public and strategic innovation programs.

The company has secured capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program, the NVIDIA Inception program and award funding via BARDA’s BLUE KNIGHT collaboration with Johnson & Johnson Innovation – JLABS. This financing base supports its early-stage research and positions Decoy within a niche of AI-driven drug discovery focused on complex infectious and oncologic indications.

Average Trading Volume: 2,306,820

Technical Sentiment Signal: Strong Sell

Current Market Cap: $4.21M

See more data about DCOY stock on TipRanks’ Stock Analysis page.